Literature DB >> 11578319

Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review.

M.S. Carey1, A.J. Dembo, J.E. Simm, A.W. Fyles, T. Treger, R.S. Bush.   

Abstract

A retrospectively designed classification using stage, residuum and a variable which combines prognostic information from both grade and histology (histology-grade variable) has been used at our institution to predict prognosis, and choose therapy in patients with ovarian carcinoma, stages I-III having no or small residuum. In this study, multivariate analysis of prognostic factors were performed over two time periods: Group 1 (1971-1978), contains the patients from which the original classification was derived, and Group 2 (1979-1985), contains a different cohort of patients who are used to test the validity and reproducibility of the original classification. Multivariate analysis showed that the prognostic significance of two variables changed over the two study periods: tumor grade, and residuum. It was found that in the ideal combination of grade and histologic type, when used in conjunction with stage and residuum in a prognostic classification, was unique to each patient cohort. Because of these changes, new and more accurate prognostic classifications were derived for Group 2. However, when all classifications were examined, (including the original), the differences in their ability to stratify patients into risk categories was negligible, and there was no major advantage to using one classification over another for clinical applications. Thus, the retrospectively derived prognostic classification using grade, instead of a combined histology-grade variable, in conjunction with the other significant prognostic factors (stage and residuum), is preferred for prospective application, and for its simplicity.

Entities:  

Year:  1993        PMID: 11578319     DOI: 10.1046/j.1525-1438.1993.03010024.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Anette Kjaerbye-Thygesen; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2012-02-24       Impact factor: 5.482

2.  Lactobacillus reuteri Releasing IL-22 (LR-IL-22) Facilitates Intestinal Radioprotection for Whole-Abdomen Irradiation (WAI) of Ovarian Cancer.

Authors:  Diala F Hamade; Alexis Espinal; Jian Yu; Brian J Leibowitz; Renee Fisher; Wen Hou; Donna Shields; Jan-Peter van Pijkeren; Amitava Mukherjee; Michael W Epperly; Anda M Vlad; Lan Coffman; Hong Wang; M Saiful Huq; Ravi Patel; Jason Huang; Joel S Greenberger
Journal:  Radiat Res       Date:  2022-07-01       Impact factor: 3.372

3.  Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: implications for adjuvant radiotherapy.

Authors:  Jee Suk Chang; Woong Sub Koom; Sang Wun Kim; Sunghoon Kim; Yong Bae Kim; Young Tae Kim; Gwi Eon Kim
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

4.  A prognostic model for ovarian cancer.

Authors:  T G Clark; M E Stewart; D G Altman; H Gabra; J F Smyth
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

Review 5.  Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future.

Authors:  Emma C Fields; William P McGuire; Lilie Lin; Sarah M Temkin
Journal:  Front Oncol       Date:  2017-08-21       Impact factor: 6.244

6.  Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment.

Authors:  Noorie Choi; Ji Hyun Chang; Suzy Kim; Hak Jae Kim
Journal:  Radiat Oncol J       Date:  2017-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.